US Stock MarketDetailed Quotes
SKYE SKYE BIOSCIENCE INC
- 2.460
- -0.200-7.52%
Close Dec 27 16:00 ET
- 2.510
- +0.050+2.03%
Post 20:01 ET
74.63MMarket Cap4.64P/E (TTM)
2.684High2.385Low177.34KVolume2.670Open2.660Pre Close436.06KTurnover1.33%Turnover RatioLossP/E (Static)30.34MShares19.41052wk High0.98P/B32.85MFloat Cap2.25052wk Low--Dividend TTM13.35MShs Float64.725Historical High--Div YieldTTM11.23%Amplitude1.440Historical Low2.458Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
SKYE BIOSCIENCE INC Stock Forum
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$
I had been eyeing this off for a while. Tried to buy in Jan at 0.019-0.020 but then left it alone as for whatever reason I wasn't able to buy.
Now I see it's gone from 0.02000 to a whopping 3.15.
Damn you Mr Market, that's ice cold!
whhhyyyyyyyyyy?!?!?!?!?! 😭😭
No comment yet